Seah Lim, MD, PhD

Founder and CEO 

Seah is the Founder and Chief Executive Officer at Medicovestor, Inc. He brings to the company more than 25 years of leadership experience in both academia and industry. His extensive experience in drug development and the biotech industry includes being a Product Development Consultant for Bausch Health, Product Development Consultant for Genzyme, Product Development Consultant for Burroughs Wellcome & Company, and Pediatric Lead in the Global Program at Sanofi. He is currently also an Independent Director for Emmaus Medicals, Inc and Business and Scientific Advisor for Genie Therapeutics, Inc . As a practicing physician until two years ago, Seah uniquely brings to the table not only his scientific and industry knowledge and know-how but also his clinical and payor reimbursement perspectives to the company. 

Seah graduated from Aberdeen University, Scotland with a commendation degree in Medicine (MB ChB), and was the most distinguished male graduand of the year. He underwent his British thesis-based MD training (mentor Professor Anthony Goldstone at University College London, London University) in cytokines and cell therapy for acute leukemias at the University College Hospital, London, and PhD training (mentors Professor Herman Waldmann at Cambridge University, and Professor Alan Burnett at Cardiff University) in antibody engineering at Cambridge University, England. He has since been Full Professor with many leadership roles (from being Program Directors to the Chief of Division) in various universities in the United Kingdom and United States, including at Brown University and University of Pittsburgh School of Medicine. 

Throughout his career, Seah has been an internationally recognized translational physician scientist. He has made numerous discoveries and holds 11 patents. He is the Section Editor for Journal of Translational Medicine, and has published more than 180 manuscripts in high impact medical and scientific journals, with more than 5000 citations. He has attracted more than $18M of research grants, including numerous grants from the National Cancer Institute.